Anti-Microbial Savior BioteQ Co., Ltd. – Trademark Portfolio

Entity Type: 99

Anti-Microbial Savior BioteQ Co., Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include S and SIPSIP. The owner is based in Kaohsiung City.

Lingya Dist.

7F.-2, No. 6, Siwei 3rd Rd.,

Kaohsiung City 802701 , TW

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

S
S
Registered 2024
SIPSIP
SIPSIP
Registered 2024

Trademark Classifications

Anti-Microbial Savior BioteQ Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Anti-Microbial Savior BioteQ Co., Ltd. have?

Anti-Microbial Savior BioteQ Co., Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Anti-Microbial Savior BioteQ Co., Ltd. file in?

Anti-Microbial Savior BioteQ Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Anti-Microbial Savior BioteQ Co., Ltd.'s most well-known trademarks?

Anti-Microbial Savior BioteQ Co., Ltd.'s registered trademark portfolio includes well-known marks such as S and SIPSIP. These are among 2 currently registered trademarks in the portfolio.

What is Anti-Microbial Savior BioteQ Co., Ltd.'s trademark registration success rate?

Anti-Microbial Savior BioteQ Co., Ltd. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.